Motexafin

Summary

Motexafin (CHEMBL2104414) is a phase-3 clinical-stage small molecule; indicated across 1 condition including prostate adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 874.1 Da · C48H67N5O10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2104414
Name	Motexafin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	151071
Molecular formula	C48H67N5O10
Molecular weight	874.1
InChIKey	JFOHFDSMPQIOES-UHFFFAOYSA-N

SMILES: CCC1=C(C2=NC1=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=C2)N5)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC

IUPAC name: 3-[4,5-diethyl-24-(3-hydroxypropyl)-16,17-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-10,23-dimethyl-13,20,25,26,27-pentazapentacyclo[20.2.1.13,6.18,11.014,19]heptacosa-1(25),2,4,6(27),7,9,11,13,15,17,19,21,23-tridecaen-9-yl]propan-1-ol

Also known as: Motexafin, Motexafina, Motexafine, MOTEXAFIN

Patent coverage: 4 distinct patent families (5 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 3 (60%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).